|
1
|
Geller DS and Gorlick R: Osteosarcoma: A
review of diagnosis, management, and treatment strategies. Clin Adv
Hematol Oncol. 8:705–718. 2010.PubMed/NCBI
|
|
2
|
Lamoureux F, Trichet V, Chipoy C,
Blanchard F, Gouin F and Redini F: Recent advances in the
management of osteosarcoma and forthcoming therapeutic strategies.
Expert Rev Anticancer Ther. 7:169–181. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gaspar N, Hawkins DS, Dirksen U, Lewis IJ,
Ferrari S, Le Deley MC, Kovar H, Grimer R, Whelan J, Claude L, et
al: Ewing sarcoma: Current management and future approaches through
collaboration. J Clin Oncol. 33:3036–3046. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Misaghi A, Goldin A, Awad M and Kulidjian
AA: Osteosarcoma: A comprehensive review. SICOT J. 4:122018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thomas MK, Tsang SW, Yeung ML, Leung PS
and Yao KM: The roles of the PDZ-containing proteins bridge-1 and
PDZD2 in the regulation of insulin production and pancreatic
beta-cell mass. Curr Protein Pept Sci. 10:30–36. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ma RY, Tam TS, Suen AP, Yeung PM, Tsang
SW, Chung SK, Thomas MK, Leung PS and Yao KM: Secreted PDZD2 exerts
concentration-dependent effects on the proliferation of INS-1E
cells. Int J Biochem Cell Biol. 38:1015–1022. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chaib H, Rubin MA, Mucci NR, Li L, Day ML,
Rhim JS and Macoska JA; Taylor JMG, : Activated in prostate cancer:
A PDZ domain-containing protein highly expressed in human primary
prostate tumors. Cancer Res. 61:2390–2394. 2001.PubMed/NCBI
|
|
8
|
Yeung ML, Tam TS, Tsang AC and Yao KM:
Proteolytic cleavage of PDZD2 generates a secreted peptide
containing two PDZ domains. EMBO Rep. 4:412–418. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang N, Wu Y, Gong J, Li K, Lin X, Chen
H, Yu Y, Gou Y, Hou J, Jiang D, et al: Germline genetic variations
in PDZD2 and ITPR2 genes are associated with clear cell renal cell
carcinoma in Chinese population. Oncotarget. 8:24196–24201.
2017.PubMed/NCBI
|
|
10
|
Panwar B, Arora A and Raghava GP:
Prediction and classification of ncRNAs using structural
information. BMC Genomics. 15:1272014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shukla GC, Singh J and Barik S: MicroRNAs:
Processing, maturation, target recognition and regulatory
functions. Mol Cell Pharmacol. 3:83–92. 2011.PubMed/NCBI
|
|
13
|
Hayes J, Peruzzi PP and Lawler S:
MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol
Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Di Leva G, Garofalo M and Croce CM:
MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tian X, Zhang J, Yan L, Dong JM and Guo Q:
MiRNA-15a inhibits proliferation, migration and invasion by
targeting TNFAIP1 in human osteosarcoma cells. Int J Clin Exp
Pathol. 8:6442–6449. 2015.PubMed/NCBI
|
|
16
|
Xu M, Jin H, Xu CX, Sun B, Mao Z, Bi WZ
and Wang Y: miR-382 inhibits tumor growth and enhance
chemosensitivity in osteosarcoma. Oncotarget. 5:9472–9483. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tsuji S, Kawasaki Y, Furukawa S, Taniue K,
Hayashi T, Okuno M, Hiyoshi M, Kitayama J and Akiyama T: The
miR-363-GATA6-Lgr5 pathway is critical for colorectal
tumourigenesis. Nat Commun. 5:31502014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou P, Huang G, Zhao Y, Zhong D, Xu Z,
Zeng Y, Zhang Y, Li S and He F: MicroRNA-363-mediated
downregulation of S1PR1 suppresses the proliferation of
hepatocellular carcinoma cells. Cell Signal. 26:1347–1354. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang SH, Zhang WJ, Wu XC, Weng MZ, Zhang
MD, Cai Q, Zhou D, Wang JD and Quan ZW: The lncRNA MALAT1 functions
as a competing endogenous RNA to regulate MCL-1 expression by
sponging miR-363-3p in gallbladder cancer. J Cell Mol Med.
20:2299–2308. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang R, Li Y, Dong X, Peng L and Nie X:
MiR-363 sensitizes cisplatin-induced apoptosis targeting in Mcl-1
in breast cancer. Med Oncol. 31:3472014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ding L, Ren J, Zhang D, Li Y, Huang X, Hu
Q, Wang H, Song Y, Ni Y and Hou Y: A novel stromal lncRNA signature
reprograms fibroblasts to promote the growth of oral squamous cell
carcinoma via LncRNA-CAF/interleukin-33. Carcinogenesis.
39:397–406. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment - where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liang W, Gao B, Fu P, Xu S, Qian Y and Fu
Q: The miRNAs in the pathgenesis of osteosarcoma. Front Biosci.
18:788–794. 2013. View
Article : Google Scholar
|
|
25
|
Tam CW, Cheng AS, Ma RY, Yao KM and Shiu
SY: Inhibition of prostate cancer cell growth by human secreted PDZ
domain-containing protein 2, a potential autocrine prostate tumor
suppressor. Endocrinology. 147:5023–5033. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tam CW, Liu VW, Leung WY, Yao KM and Shiu
SY: The autocrine human secreted PDZ domain-containing protein 2
(sPDZD2) induces senescence or quiescence of prostate, breast and
liver cancer cells via transcriptional activation of p53. Cancer
Lett. 271:64–80. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li M, Guan X, Sun Y, Mi J, Shu X, Liu F
and Li C: miR-92a family and their target genes in tumorigenesis
and metastasis. Exp Cell Res. 323:1–6. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Olive V, Jiang I and He L: mir-17-92, a
cluster of miRNAs in the midst of the cancer network. Int J Biochem
Cell Biol. 42:1348–1354. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou T, Zhang G, Liu Z, Xia S and Tian H:
Overexpression of miR-92a correlates with tumor metastasis and poor
prognosis in patients with colorectal cancer. Int J Colorectal Dis.
28:19–24. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hu F, Min J, Cao X, Liu L, Ge Z, Hu J and
Li X: MiR-363-3p inhibits the epithelial-to-mesenchymal transition
and suppresses metastasis in colorectal cancer by targeting Sox4.
Biochem Biophys Res Commun. 474:35–42. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen Y, Lu X, Wu B, Su Y, Li J and Wang H:
MicroRNA 363 mediated positive regulation of c-myc translation
affect prostate cancer development and progress. Neoplasma.
62:191–198. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang K, Yan L and Lu F: miR-363-3p
Inhibits Osteosarcoma Cell Proliferation and Invasion via Targeting
SOX4. Oncol Res. 27:157–163. 2019. View Article : Google Scholar : PubMed/NCBI
|
